Mind Medicine Inc.

The psychedelics space is heating up, and major players have taken notice. The market is bolstered by a growing number of decriminalization movements across the United States, as well as an increasing number of market participants, including names like COMPASS Pathways PLC (NASDAQ: CMPS), Field...

Compass Pathways Files for an IPO at NASDAQ UK-based Compass Pathways wants to become the first psychedelics company to list on a major U.S. stock exchange. The psilocybin research company intends to make its initial public offering (IPO) through NASDAQ under the ticker symbol...

FDA Expands Psychiatric Indications For Nasal Spray Ketamine Last week, the FDA approved suicidal tendencies as additional qualifying symptoms for the application of Spravato, a ketamine nasal spray used in psychiatric treatment. Spravato is the brand name for esketamine, a chemical sibling of...

District of Columbia To Include Psychedelics Decriminalization Measure on November Ballot The District of Columbia will likely become the nation’s second jurisdiction to include a psychedelics decriminalization measure in November. Oregon made a similar announcement last week, and will...

Psyched is a bi-monthly column covering the most important developments in the industry of medicinal psychedelics. We hope you follow us periodically as we report on the growth of this exciting new industry. Silo Wellness To Go Public With Reverse Takeover Of Yukoterre Resources  Oregon-...

Biopharmaceutical and psychedelics research company Mind Medicine Inc. (NEO:MMED) (OTC: MMEDF)  announced Thursday that it will begin studying DMT’s effects on humans in a Phase 1 clinical trial conducted in collaboration with University Hospital Basel in Switzerland. Understanding The...

Psyched is a bi-monthly column covering the most important developments in the industry of medicinal psychedelics. We hope you follow us periodically as we report on the growth of this exciting new industry. New Leaf Brands Changes Name To Mydecine, Announces New HQ  Cannabis company NewLeaf...

Psyched is a bi-monthly column covering the most important developments in the industry of medicinal psychedelics. We hope you follow us periodically as we report on the growth of this exciting new industry. ATAI Life Sciences Announces Closing Of $24M Convertible Round  On Thursday, biotech...

Psyched is a bi-monthly column covering the most important developments in the industry of medicinal psychedelics. We hope you follow us periodically as we report on the growth of this exciting new industry. Versión en Español en El Planteo. MindMed Inks Deal With Switzerland...

Neuro-pharmaceutical and psychedelics company Mind Medicine Inc. (NEO: MMED) (OTC: MMEDF) has acquired exclusive rights to data, compounds, and patents for research with LSD and other psychedelics from the Liechti laboratory in Switzerland’s University Hospital Basel. Exploring High-Dose LSD...

The Canadian NEO Exchange announced Tuesday that neuro-pharmaceutical company Mind Medicine Inc. (OTC:MMEDF) (NEO: MMED) will make its public market debut under the symbol "MMED." The exchange's approval of MindMed makes it the first psychedelic company to be publicly listed,...